Gyre Therapeutics (GYRE) Deferred Taxes (2023 - 2026)
Gyre Therapeutics (GYRE) reported Deferred Taxes of -$738000.0 for Q1 2026, down 286.39% year-over-year from $395949.4 in Q1 2025, and down 748.28% quarter-over-quarter from -$87000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Deferred Taxes (2023 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 4 years of Deferred Taxes data on file, last reported at -$738000.0 in Q1 2026.
- Deferred Taxes for Q1 2026 came in at -$738000.0, down 286.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.7 million (down 88.18% YoY), and the FY2025 annual result was -$1.1 million, down 10.68% from the prior year.
- Deferred Taxes slipped to -$738000.0 in Q1 2026 per GYRE's latest filing, from -$87000.0 in the prior quarter.
- Over five years, Deferred Taxes peaked at -$87000.0 in Q4 2025 and troughed at -$738000.0 in Q1 2026.
- A 4-year average of -$334083.3 and a median of -$306500.0 in 2024 frame the typical range for Deferred Taxes.
- The sharpest annual moves came in 2025 and 2026: Deferred Taxes surged 85.3% in 2025, then sank 286.39% in 2026.
- A 4-year view of Deferred Taxes shows it stood at -$403000.0 in 2023, then tumbled by 46.9% to -$592000.0 in 2024, then surged by 85.3% to -$87000.0 in 2025, then sank by 748.28% to -$738000.0 in 2026.
- Business Quant data shows GYRE's Deferred Taxes at -$738000.0 in Q1 2026, -$87000.0 in Q4 2025, and -$531000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -859,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -65.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | -738,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -738,000.00 |
| Dec 31, 2025 | -87,000.00 |
| Sep 30, 2025 | -531,000.00 |
| Jun 30, 2025 | -300,000.00 |
| Mar 31, 2025 | -191,000.00 |
| Dec 31, 2024 | -592,000.00 |
| Jun 30, 2024 | -97,000.00 |
| Mar 31, 2024 | -313,000.00 |
| Dec 31, 2023 | -403,000.00 |
| Sep 30, 2023 | -199,000.00 |
| Jun 30, 2023 | -230,000.00 |
| Mar 31, 2023 | -328,000.00 |